FR960299A - - Google Patents
Info
- Publication number
- FR960299A FR960299A FR960299DA FR960299A FR 960299 A FR960299 A FR 960299A FR 960299D A FR960299D A FR 960299DA FR 960299 A FR960299 A FR 960299A
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR960299A true FR960299A (ru) | 1950-04-15 |
Family
ID=1562020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR960299D Expired FR960299A (ru) |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR960299A (ru) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070767B1 (fr) * | 1981-07-17 | 1985-04-10 | Roussel-Uclaf | Nouveaux dérivés de la quinoléine, leurs sels, leur préparation, leur application comme médicaments et les compositions les renfermant |
| US8829204B2 (en) | 2004-06-24 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US9139530B2 (en) | 2005-12-28 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
-
0
- FR FR960299D patent/FR960299A/fr not_active Expired
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0070767B1 (fr) * | 1981-07-17 | 1985-04-10 | Roussel-Uclaf | Nouveaux dérivés de la quinoléine, leurs sels, leur préparation, leur application comme médicaments et les compositions les renfermant |
| US8829204B2 (en) | 2004-06-24 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US9090619B2 (en) | 2004-06-24 | 2015-07-28 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US10662192B2 (en) | 2004-06-24 | 2020-05-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US11291662B2 (en) | 2005-12-28 | 2022-04-05 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9139530B2 (en) | 2005-12-28 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9931334B2 (en) | 2005-12-28 | 2018-04-03 | Vertex Pharmaceuticals Incorporated | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US10537565B2 (en) | 2005-12-28 | 2020-01-21 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US11564916B2 (en) | 2008-08-13 | 2023-01-31 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US11147770B2 (en) | 2012-02-27 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US11752106B2 (en) | 2012-02-27 | 2023-09-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |